Table 3 Correlation between the expression level of microRNAs miR-296-5p, miR-452, miR-183* and miR-200c and the clinical and pathological characteristics of the LSCC patients enrolled in the study

Age (years)

≤60 years

6 (35.3)

10 (58.8)

8 (47.1)

8 (47.1)

8 (47.1)

8 (47.1)

8 (50.0)

8 (47.1)

>60 years

11 (64.7)

7 (41.2)

9 (52.9)

9 (52.9)

9 (52.9)

9 (52.9)

8 (50.0)

9 (52.9)

p (2-sided)

NS

NS

NS

NS

Gender

Female

2 (11.8)

2 (11.8)

2 (11.8)

2 (11.8)

2 (11.8)

2 (11.8)

2 (12.5)

2 (12.5)

Male

15 (88.2)

15 (88.2)

15 (88.2)

15 (88.2)

15 (88.2)

15 (88.2)

14 (87.5)

15 (88.2)

p (2-sided)

NS

NS

NS

NS

Smoking

No

0 (0)

3 (17.6)

1 (5.9)

2 (11.8)

0 (0)

3 (17.6)

2 (12.5)

1 (9.1)

Yes

17 (100)

14 (82.4)

16 (94.1)

15 (88.2)

17 (100)

14 (82.4)

14 (87.5)

16 (94.1)

p (2-sided)

NS

NS

NS

NS

Tumor site*

Glottic

15 (88.2)

12 (70.6)

14 (82.4)

13 (76.5)

14 (82.4)

13 (76.5)

14 (87.5)

12 (70.6)

Supraglottic

2 (11.8)

5 (29.4)

3 1 (7.6)

4 (23.5)

3 (17.6)

4 (23.5)

2 (12.5)

5 (29.4)

p (2-sided)

NS

NS

NS

NS

Tumor stage

I

7 (41.2)

9 (52.9)

9 (52.9)

7 (41.2)

7 (41.2)

9 (52.9)

7 (43.8)

9 (52.9)

II

10 (58.8)

8 (47.1)

8 (47.1)

10 (58.8)

10 (58.8)

8 (47.1)

9 (56.2)

8 (47.1)

p (2-sided)

NS

NS

NS

NS

Radiosensibility

Sensivite

11 (64.7)

3 (17.6)

8 (47.1)

6 (35.3)

9 (52.9)

5 (29.4)

7 (43.8)

7 (41.2)

Resistant

6 (35.3)

14 (82.4)

9 (52.9)

11 (64.7)

8 (47.1)

12 (70.6)

9 (56.2)

10 (58.8)

p (2-sided)

0.01

NS

NS

NS